The meningococcal conjugate, or MenACWY vaccine (often called by brand names such as Menactra, Menveo, and MenQuadfi) features a vaccine that targets four of the most common types of bacterial ...

A life-saving meningococcal vaccine covering all five common strains of the deadly disease could soon be available thanks to ...

Stay updated on the latest vaccination recommendations to know when and how to get vaccinated. Meningococcal disease is an infection caused by Neisseria meningitidis, a type of meningococcal ...

The concomitant administration of multiple vaccines at ... 20 and 24 mMU/mL for types 6, 11, 16 and 18, respectively, post-vac Intergroup difference –5% Meningococcal hSBA titer ≥4 % of ...

The FDA has started a review of GSK’s five-in-one meningococcal vaccine, cueing up a decision in mid-February next year, as it tries to chase down a rival candidate from Pfizer cleared last year.

GSK has garnered FDA approval for its pentavalent meningococcal vaccine Penmenvy, tipped as one of its major launches for 2025 and a rival to Pfizer's first-to-market Penbraya. The shot protects ...

Based on type, conjugate vaccines segment is expected to account for half of the revenue share in the global meningococcal vaccines market by 2025. This is due to advantages of conjugate vaccines ...

Meningococcal vaccination is vital for teens to prevent serious infections like meningitis and ensure long-term protection.

ACIP recommends pentavalent meningococcal vaccine Penmenvy (meningococcal Groups A, B, C, W, and Y vaccine) for individuals 10 through 25 years of age.

Researchers at the Wesfarmers Centre of Vaccines and Infectious Diseases at The Kids Research Institute Australia, alongside ...

The ACIP voted that Penmenvy may be used as part of the adolescent meningococcal vaccination schedule as an alternative to separate administration of MenACWY and MenB. The Centers for Disease ...

. The global meningococcal vaccines market size is anticipated to grow nearly 2X, expanding from USD 4.53 Bn in 2025 to USD 9.05 Bn by 2032, recording a CAGR of 10.4% throughout the forecast ...